Weight loss jabs linked to potentially fatal side effects, says new report
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects.
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal.
Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: https://t.co/Ahd6YqXIif pic.twitter.com/WLwEfZM2qR
— NHS Cheshire and Merseyside (@NHSCandM) June 24, 2025
This includes:
181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died.
116 reported reactions of this kind linked to liraglutide, one of which was fatal.
113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died.
101 reported reactions of this kind linked to exenatide, three people died.
52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug.
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/YcfHOz32fx
— We are Primary Care (@PrimaryCareNHS) June 27, 2025
Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup.
The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme.
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study.
Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes.
GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss.
🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… pic.twitter.com/fb2KdaXIou
— Royal College of General Practitioners (@rcgp) June 23, 2025
Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move.
You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night.
Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss.
If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective.
More Mounjaro news...
Who is eligible for Mounjaro on the NHS?
Urgent holiday warning for Mounjaro users issued
Mounjaro warning as summer temperatures rise
Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs.
Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea.
And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients.
Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.
'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup.
'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme.
'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.'
Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects.
'We believe there is real potential to minimise these with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Traveling With Ozempic This Summer? Here's What Doctors Want You to Know
Traveling while taking a GLP-1 medication like Ozempic or Wegovy comes with its own set of challenges, and those challenges only multiply in the summer. Whether you're navigating a heat wave, spending hours on a plane or just trying to keep up with your summer routine, it's not always easy to stay consistent with your medication or manage potential side effects like nausea and fatigue. Hot weather alone can be a major obstacle, since most GLP-1 medications need to be kept refrigerated or at a stable temperature until use. Add in airport security, changing time zones and irregular meals, and it's easy to feel overwhelmed. But with the right planning, it's entirely possible to travel safely and comfortably while staying on track with your treatment. More from Flow Space 6 Expert Recommended Steps to Take Before the FDA Cracks Down on GLP-1 Drugs Here's what to know before you hit the road or friendly skies this summer. Traveling with GLP-1 medications requires some planning, especially during the summer months. When in room temperature conditions, opened pens can remain at room temperature for up to 28 days. However, if you are traveling by car in the summer heat, it is best to keep your medication in an insulated bag with cooling packs, Dr. Britta Reierson, a board-certified family physician and obesity medicine specialist at metabolic health company knownwell, tells Flow Space. 'Ensure that the packs don't directly touch the medication to avoid freezing,' she says. 'Store the medication out of direct sunlight and heat sources, and if you have overnight stops, use refrigeration whenever possible. You can even consider a portable mini-fridge that can go in the car for longer trips.' And what about while flying? Reierson says if your summer plans have you traveling by air, it is important to always carry your medication in your carry-on luggage to maintain consistent temperature and inform TSA officers that you are carrying injectable medication. Keep the medication in its original packaging with the prescription label. 'Also, use cooling packs to keep the medication cool during the flight,' she adds 'For international travel, I have provided my patients with a letter to present to TSA and customs if required. I recommend checking with state and country specific traveling with medication requirements prior to travel.' GLP-1s are known to cause side effects like nausea, an upset stomach, diarrhea and constipation. Not to mention, most GLP-1s are given via injection, which can sometimes cause pain at the site and might even require a band-aid. Because of this, Reierson recommends packing a 'medication go-bag.' To prepare, she suggests including the following: All prescription medications—enough to cover the entire trip, plus a couple extra days to cover for unexpected travel delays All injection supplies needed Over-the-counter medications, like pain relievers, antihistamines, antacids and anti-diarrheal medications First-aid supplies, such as bandaids, antiseptic and cleaning wipes, antibiotic ointment, sunscreen and insect repellent A printed list of your medications, dosings and a copy of health insurance/dental insurance card And while you may think you've packed and prepared everything needed, it's also important to start preparing your body in the days leading up to your travels. Dr. Shaline Rao, chief of cardiology and vice chair of the Department of Medicine Hospital Operations at NYU Langone Hospital—Long Island, recommends not starting a new medication or dose change in the days before travel as you may find yourself facing unexpected side effects. She says that with travel comes changes in hydration, frequency of meals, as well as the possibility of nausea or low appetite. If you have strong symptoms or are prone to these types of issues, talk to your physician before traveling for possible supportive care plans. 'For the majority of patients, making sure to stay hydrated, avoid extreme temperatures and eat small meals throughout the day should be sufficient,' she says. 'Making sure to take cues from your body is important. If you need time to rest, take the time you need.' If you forget a dosage during travel it will be easier to manage if you are traveling nationally, not abroad. You may consider transferring your prescription to a local branch of your national chain pharmacy, or contacting your doctor to call in a prescription to a nearby pharmacy. If you are abroad, you may need to find a local pharmacy or healthcare provider to prescribe the medication. 'In some countries you may be able to find GLP-1 medications for purchase without a prescription at a local pharmacy, however it is important to ensure you're buying from a reputable source to avoid counterfeit medications,' says Reierson. And if you fall off your dosing routine during travel? Rao says it is best to consult with your provider for guidance, but in general, you will be able to get back on a routine and be OK. 'If you do not have diabetes, then the consequence of a missed dose or delayed dose is likely low and you can work with your team to set up a resumed schedule,' she says. 'These medications are typically once a week, so the average traveler can get back on track quickly. This is why it is best to travel with extra supplies so as to minimize the stress of changes during travel.'
Health Line
5 hours ago
- Health Line
Will Medicare Pay for the Pill Form of Semaglutide?
Semaglutide is a prescription medication. Injectable forms of the drug are available under the brand names Ozempic and Wegovy. The pill form of semaglutide is available as the brand-name drug Rybelsus. Medicare drug plans usually cover Rybelsus when doctors prescribe it for type 2 diabetes. Medicare coverage of the pill form of semaglutide The Food and Drug Administration (FDA) has approved Rybelsus, the pill form of semaglutide, to lower blood sugar levels when taken along with exercise and diet in people with type 2 diabetes. If you have a Part D prescription drug plan or a Medicare Advantage (Part C) plan with drug benefits, your plan may cover Rybelsus if your doctor prescribes it for this FDA-approved use. Every Medicare drug plan has a list of covered drugs called a formulary. Not all Medicare plans may cover Rybelsus. If you're unsure whether your plan may cover Rybelsus, check its formulary or contact a plan representative. Medicare coverage of semaglutide for weight loss Some doctors prescribe the pill form of semaglutide off-label to assist with weight loss. 'Off-label' use describes taking a drug for a purpose the FDA hasn't approved. Medicare doesn't cover drugs when people take them off-label. For this reason, it doesn't cover the pill form of semaglutide for weight loss.
Yahoo
7 hours ago
- Yahoo
Weight loss jabs linked to potentially fatal side effects, says new report
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects. Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: — NHS Cheshire and Merseyside (@NHSCandM) June 24, 2025 This includes: 181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died. 116 reported reactions of this kind linked to liraglutide, one of which was fatal. 113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died. 101 reported reactions of this kind linked to exenatide, three people died. 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug. These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: — We are Primary Care (@PrimaryCareNHS) June 27, 2025 Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. 🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… — Royal College of General Practitioners (@rcgp) June 23, 2025 Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective. More Mounjaro news... Who is eligible for Mounjaro on the NHS? Urgent holiday warning for Mounjaro users issued Mounjaro warning as summer temperatures rise Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
